Seeking partners
The drug discovery specialist Scottish Biomedical Ltd has identified a number of actives from its lead generation library, which it says are high quality lead-like compounds with good physicochemical properties, amenable to rapid optimisation.
These compounds show potent and selective activity against their target. The company, based in Glasgow, Scotland, is now looking for co-development partners. The leads include a novel class of compounds which show selective and potent activity against phosphodiesterase 11A, which have shown activity in an animal model of schizophrenia.
A second, tyrosine kinase inhibitor SB41947, inhibits the growth of a panel of solid and haematological tumour cell lines, and shows selectivity for a subset of auto-inhibited receptor tyrosine kinases implicated in aberrant cancer cell growth.
The company has also identified novel small molecules that activate alpha secretase for the treatment of Alzheimer’s disease.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 